Surgical recording device differentiates between novice, expert surgeons

Researchers from the Keck Medicine of University of Southern California (USC) have found using a recording device during surgical procedures can differentiate between novice and expert surgeons. Findings, published in The Journal of Urology, aimed to improve the evaluation process of surgeon proficiency and standardizing credentialing.

Using the dVLogger recording device, researchers were able to capture anonymized video and movement data. The device can be attached to the da Vinci Surgical System, an FDA-approved robotic surgical platform for general laparoscopic surgery.

"Robotic surgery has been widely adopted by urologic surgeons, but methods of assessing proficiency vary widely between institutions," said lead author Andrew Hung, MD, assistant professor at USC. "In order to be credentialed by institutions to use the robotic system, surgeons must be evaluated by their peers for a handful of procedures, but the evaluations are not ongoing, and sometimes evaluators don't agree on what constitutes proficiency."

The study included data from 100 procedures on surgeon proficiency in performing four basic prostate surgery steps. Results showed the tool was able to differentiate between novice and expert surgeons by measuring the time it took to complete steps, distance of instrument and camera travel, and frequency of camera movements.

"The dVLogger records the surgeon's movements, capturing where the instruments are and how the surgeon is moving the instruments," Hung says. "We now have an opportunity to put surgeon proficiency under the microscope and see what role it plays in patient outcomes.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.